SinglePoint (OTC: $SING) and Smart Cannabis Corp. Sign Joint Venture to Integrate, Distribute 'SMART APP' for Cannabis Businesses

SinglePoint (OTC: $SING) and Smart Cannabis Corp. Sign Joint Venture to Integrate, Distribute 'SMART APP' for Cannabis Businesses

SEATTLE - December 5, 2017 (Investorideas.com Newswire) SinglePoint, Inc. (OTC:SING) today announces a joint venture relationship with Smart Cannabis Corporation (SCNA) (www.smartcannabis.com) in which SinglePoint will license and market Smart Cannabis' SMART APP, an industry specific application that enables cultivators to control entire operations from a mobile device. The SMART APP is leading the way in efficiently cultivating cannabis through the introduction of IoT technology (Internet of Things) to greenhouses. This SMART APP IoT technology measures everything from nutrient levels in soil to watering cycles, to parts per million of carbon dioxide in the air. SinglePoint and Smart Cannabis Corp. will also work together to integrate SinglePoint's bitcoin payment solution. This gives cultivators the ability to collect payment for their sales via the payment application, making for a safer and more secure transaction.

Read this news in full at http://www.investorideas.com/CO/SING/news/2017/12051SMARTAPP.asp

"Cultivators need a solution to secure their payments. We are looking to provide a solution that can be used from seed to sale, the entire life cycle. The transaction from a cultivator to a processor or dispensary can be huge, over $150,000 per transaction, and it is simply not safe or efficient to carry that kind of cash to a transaction. We believe we can help secure and track this transaction with our solution," states SinglePoint President Wil Ralston.

Additionally, SinglePoint and Smart Cannabis Corp. will work together to finalize a track and trace solution. This solution, already available for Smart Cannabis cultivator customers, be developed by SinglePoint and deployed to a consumer base that will bring the solution full circle.

"Consumers who walk into a dispensary, where a cultivator is using our system, will be able to see how, when, and where the product was grown. There is no other system on the market like it and we plan to be the first company to use transparent and traceable blockchain technology to bring this "track and trace" product knowledge to consumers," said Ralston.

John Taylor, president of Smart Cannabis Corp., said the company is excited to "team up" with SinglePoint.

"They are an ideal partner for us to expand our business beyond California for both our current products, our line of innovative automation, and our trace and tracking software solution for cultivators. This joint venture with SinglePoint will give us the ability to market our products on a broader scale. In addition, we believe the uptrend in cryptocurrency use in the cannabis marketplace will continue to expand, and being part of their exchange will help us grow our base business."

SinglePoint is moving into what has been labeled as California's "Green Rush" in a big way. Through joint ventures and acquisitions the company has solidified its beachhead in a state that projects annual cannabis sales around $7 billion. According to Grand View Research, the medical marijuana market is expected to reach a value of USD $55.8 billion by 2025.

SinglePoint and Smart Cannabis Corporation are moving into this major market offering top tier solutions that will drive revenue for both companies.

"We are very impressed with the results that Smart Cannabis has quickly achieved in California, and we believe this relationship with them provides a great deal of synergy, both in California and in the nationwide cannabis business. The company is building a truly innovative product. Our expertise in payment processing and point of sale systems is a perfect fit for the track and trace technology they have developed to date. Our overall goal is to have a fully integrated solution for businesses to manage their day-to-day operations from beginning to end, and Smart Cannabis operates to that same goal with their automated greenhouse solutions. We are glad they have turned to us to collaborate on their software solutions, and to be a part of our bitcoin exchange," said Greg Lambrecht, CEO and founder of SinglePoint.

About SinglePoint Inc.

SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry.

Connect on social media at:

www.facebook.com/SinglePointMobile

www.twitter.com/_SinglePoint_

www.linkedin.com/company/SinglePoint

For more information, visit www.SinglePoint.com

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Contact:

SinglePoint, Inc.
Greg Lambrecht
602.481.1544

Communications Contact:
NetworkNewsWire (NNW) 
New York, New York 
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Disclosure: SinglePoint, Inc. (OTC: $SING) is featured on the 420 Cannabis Investor Ideas of 2017 at 

www.420cannabisinvestorideas.com

SinglePoint, Inc. (OTC: SING) is a featured company on Investorideas.com
View the profile on Investorideas.com

Disclaimer: This directory is not a recommendation to buy or sell securities or products or services Investorideas.com charges a fee for placement. The directory is not an endorsement or recommendation but meant to be an investor resource/ due diligence tool.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: Companies Featured on the 420 Cannabis Investor Ideas have paid a one-time fee of Up to $1000 to be featured on the directory and SING is also a paid featured cannabis and bitcoin company for news and PR social media

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Bitcoin, Blockchain and Digital Currency Stocks and ICO's

Like Bitcoin, Blockchain and Digital Currency Stocks? View our Bitcoin, Blockchain and Digital Currency Stocks Directory

Revive Therapeutics (TSXV: $RVV.V) (OTCQB: $RVVTF) Announces Update on Development of Datametrex Artificial Intelligence Component in #Blockchain Enabled Patient-Focused Program for Medical #Cannabis Sector

Revive Therapeutics (TSXV: $RVV.V) (OTCQB: $RVVTF) Announces Update on Development of Datametrex Artificial Intelligence Component in #Blockchain Enabled Patient-Focused Program for Medical #Cannabis Sector

TORONTO, ONTARIO - December 4, 2017 (Investorideas.com Newswire) Revive Therapeutics Ltd. ("Revive" or the "Company") (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors, today announced an update on the development of the Artificial Intelligence ("AI") component for Revive's proposed proprietary patient-focused program dedicated to the medical cannabis industry enabled by Blockchain technology. This update follows Datametrex AI Limited ("Datametrex") (TSX VENTURE:DM)(FRANKFURT:D4G) recent announcement of Datametrex's wholly owned subsidiary, Nexalogy Environics Inc. ("Nexalogy"), entered into a license and development agreement with Revive.

Read this news in full at http://www.investorideas.com/news/2017/marijuana/12041TSXVRVV.asp

Revive is aiming to incorporate Nexalogy's proprietary social data discovery solution, NexaIntelligence, to unlock the value of data related to medical cannabis collected from social media networks and internet environments such as discussion forums, blogs and news sites. Through data mining and analytics, information aggregated from independent sources on the internet will aim to provide authentic insights and uses of cannabis on a variety of medical conditions. With its unique, easy-to-understand visuals in a highly functional interface, NexaIntelligence, is able to conduct a deep analysis of the ever-growing volume of online data of medical cannabis and catch the valuable signals that lead to strategic insights and actionable intelligence.

"We are very excited about Nexalogy's NexaIntelligence social data software solution as it provides us with a proprietary data collection strategy and enables us to unlock the value of information, by artificial intelligence, currently being generated in numerous independent social networks and environments on the internet," said Fabio Chianelli, President of Revive. "We are focused on building a proprietary patient-centered platform dedicated to the medical cannabis industry that will leverage the privacy, security, and information sharing features of blockchain and the data mining, predictive and machine learning features of AI with the aim to engage, acquire, retain, and support medical cannabis patients. The AI component will provide insights, analytics and recommendations that may offer significant value to licensed producers of cannabis, healthcare professionals, and clinical researchers."

Andrew Ryu, Chairman and CEO of Datametrex added, "We are very encouraged to see our AI component provide such relevancy to Revive and the cannabis sector. This is an explosive area and we will be delivering vital data around patients."

About Datametrex AI Limited

Datametrex (TSX VENTURE:DM)(FRANKFURT:D4G) is focused on the collection of retail sales data, providing government agencies and Fortune 500 corporations with artificial intelligence technology and implementing blockchain solutions for secure data transfers. The company is planning on integrating the DataTap environment to decentralized blockchains to further authenticate and validate the data collected. To learn more about Datametrex, visit: www.datametrex.com.

About Nexalogy

Nexalogy is a wholly-owned subsidiary of Datametrex AI Limited. Nexalogy AI solutions unlock valuable insights from social media data. Through its proprietary semantic clustering algorithms, it provides insights and analysis that are not available through traditional business intelligence technology. This technology makes data more relevant and is the missing link in providing actionable social media intelligence to governments and organizations all over the world. To learn more about Nexalogy, visit: www.nexalogy.com.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and pharmaceutical sectors. Additional information on Revive is available at www.ReviveThera.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

This news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute "forward-looking information" that involves known and unknown risks and uncertainties, which are not comprised of historical facts, and most of which are beyond the control of Revive. Forward-looking statements include estimates and statements that describe Revive's future plans, objectives or goals, including words to the effect that Revive or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as "believes", "anticipates", "intends", "expects", "estimates", "may", "could", "would", "will", or "plan", and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company's drug research and development, and commercialization plans; the Company's research, development and commercialization plans for plant-based therapies, including cannabinoid and its delivery technology; the timing of operations; the Company's research and development, and commercialization plans for blockchain and artificial intelligence; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management's expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company's drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect and no assurance can be given that such events will occur in the disclosed time frames or at all.

Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company's ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive's Management's Discussion & Analysis for the period ended June 30, 2017 and Revive's other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Contact Information

Revive Therapeutics Ltd.
Craig Leon
Chief Executive Officer
(416) 272-5525
craig@revivethera.com
www.revivethera.com

Marijuana / Hemp Stocks

Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

             

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

New #TSX & #CSE #Marijuana and #Cannabis #Stocks Added to Investor Ideas; $CHOO.C, $BLGV.C & $DM.V

New #TSX & #CSE #Marijuana and #Cannabis #Stocks Added to Investor Ideas; $CHOO.C, $BLGV.C & $DM.V  

Point Roberts, WA, Delta BC – December 1, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its cannabis /hemp stock directory for investors following the sector.

Investorideas.com tracks cannabis and hemp publicly traded companies on the TSX, TSX.V, CSE, OTC, NYSE, NASDAQ, ASX  and global stock exchanges and makes ongoing additions to its stock directories for its members.  Free previews of all directories are available to the public with full login access only accessible to members

All of the recently added cannabis companies are listed on Canadian Exchanges (TSX Venture & CSE).

Read this news in full at http://www.investorideas.com/news/2017/marijuana/12011Stocks.asp

Companies include a new marijuana producer in British Columbia, a supplier of organic fertilizers and blockchain technology for the cannabis industry and Datametrex AI Limited (TSX:DM.V), whose subsidiary Nexalogy Environics is working with Revive Therapeutics Ltd. (TSXV:RVV) (OTCQB:RVVTF) to develop the Artificial Intelligence (“AI”) component in Revive’s proprietary patient-focused program enabled by Blockchain technology and dedicated to the medical cannabis industry.

New Marijuana Companies Added to the Investor cannabis stock directory:

Choom Holdings Inc. (CSE:CHOO) Formery Standard Graphite Corp - was created for and inspired by the Choom Gang; a group of high school buddies in Honolulu during the early 1970's who loved to smoke weed---or as they called it, "choom". Now, after four decades, Choom™ is bringing the spirit of Hawaii to the Okanagan and Canada. We're planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb.

Belgravia Capital International Inc. (CSE:BLGV) is focused on the provision of clearly value-added services to the international Cannabis industry.  This includes the production of specialized organic fertilizers for Cannabis Sativa plants, and the organization and development of blockchain technology software for seed to sale tracking and quality attestation of intermediate and consumer products.  The wholly owned subsidiary of Belgravia, ICP Organics, is a research and development company incorporating agronomic and health perspectives in the Cannabis space.  Blockchain technology, with its ability to provide robust and immutable histories of product tracking and also low cost integrated data bases for the Cannabis industry, is an ideal value-added approach to generating profitable Cannabis production and distribution activities.  Belgravia is also developing a royalty-streaming subsidiary.

Datametrex AI Limited (TSX:DM.V; FSE:D4G) is focused on the collection of retail sales data, providing Government Agencies and Fortune 500 corporations with Artificial Intelligence solutions and implementing blockchain solutions for secure data transfers. The company is planning on integrating the DataTap environment to decentralized blockchains to further authenticate and validate the data collected. BLOCKCHAIN: Company’s wholly owned subsidiary, Nexalogy Environics Inc., has entered into a license and development agreement (the “Agreement”) with Revive Therapeutics Ltd. ("Revive") (TSXV:RVV) (OTCQB:RVVTF) to develop the Artificial Intelligence (“AI”) component in Revive’s proprietary patient-focused program enabled by Blockchain technology dedicated to the medical cannabis industry.

The complete marijuana/hemp stock list available for purchase in a PDF format:

http://www.investorideas.com/dirs/stocklist.asp

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Investorideas.com cannabis/marijuana and hemp content now includes: http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the AI site Global Cannabis Investing at www.Globalcannabisinvesting.com

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Services for Publicly traded and private companies: http://www.investorideas.com/Investors/Services.asp

Investorideas is Listed on The Canadian Securities Exchange (CSE) Directory of Service Providers

http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Marijuana / Hemp Stocks

Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

#AppSwarm and #SinglePoint (OTC: $SING) Finalize Plans for #Cannabis and #Bitcoin Focused #Applications and #Technology

#AppSwarm and #SinglePoint (OTC: $SING) Finalize Plans for #Cannabis and #Bitcoin Focused #Applications and #Technology

TUSLA, Okla. - November 29, 2017 (Investorideas.com Newswire) AppSwarm, Inc. (SWRM) ("the Company") A technology company specializing in the accelerated development and publishing of mobile apps has completed development plans with SinglePoint (OTC:SING) to conduct a shared roll-out of mobile applications specifically geared to solve issues in the cannabis space using the Blockchain technology and Bitcoin payment options. The applications and tech will be modelled and marketed under SinglePoint's SingleSeed subsidiary (www.SingleSeed.com), while AppSwarm (www.app-swarm.com) will provide the necessary technical support and application development. The venture calls for a 50/50 revenue share on all products to be deployed.

Read this news in full at http://www.investorideas.com/CO/SING/news/2017/11291AppSwarm.asp

The Crypto and cannabis market is in need for technology solutions that can advance productivity and do it safely. AppSwarm and SinglePoint intend to develop mobile applications that address these needs by creating a system that allows a business to see what is going on in the market around them. The mobile apps and tech created will also modernize the consumer experience by adding in SinglePoint's payment features, as well as a multitude of other functionalities that are currently proprietary to AppSwarm.

"This JV with SinglePoint allows them unfettered access to all of the technology we currently have in-house, as well as what we are and will be developing in the near future. With the Crypto space expanding at mind-boggling speed it only makes sense to be partnering with such a prestigious industry leader in SinglePoint," stated AppSwarm CEO Ron Brewer.

SinglePoint and AppSwarm plan to launch the first application mid-January 2018 as well as release additional applications shortly after the initial launch. The first application will provide a base for additional applications and will be a service-based application for the business-to-business (B2B) and business-to-consumer (B2C) markets.

The cryptocurrency market cap has reached $300 billion, according to marketcap.com, with gains in many of the major currencies, particularly as Bitcoin price has jumped over $9,500. The market cap has been driven by a number of factors, but Bitcoin continues to maintain a 53 percent dominance in the total cap.

The market cap surge has been spurred on by a huge jump in the value of Bitcoin, but other coins have also had excellent weeks. Ethereumand Litecoin had particularly strong weeks, with Ethereum posting an all-time high and other altcoins like Monero, IOTA, and Dash all had a strong showing as well.

The cannabis market is projected to reach $50 billion by 2025. Currently, cannabis is legal in 29 states and the District of Columbia. These mobile applications will be available for use in all states. As new states legalize, the companies will look to grow alongside the new states opening to legalized cannabis sales.

SinglePoint CEO Greg Lambrecht states, "We are excited to be working with AppSwarm on our proposed solutions. What they have shown us they have in-house supports what we are looking to roll out into the industry. We will work with what they have and continue to build new applications to add value. This is really a win-win partnership for both teams as they have great technology and we have capital to roll out a national campaign to quickly start driving positive revenue for both companies."

About AppSwarm

We develop and publish mobile gaming and business apps, with a focus on accelerating the development of free to play mobile games and fast-track them to market. We partner with game and business developers through joint ventures, royalty agreements, marketing partnerships, and outright purchases through our publicly-traded company on the OTC Markets, ticker SWRM.

For more information, visit us at www.app-swarm.com, or follow us on facebook.com/AppSwarm or Twitter twitter.com/AppSwarm

About SinglePoint Inc.

SinglePoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed the company is providing products and services to the cannabis industry.

For more information, visit www.SinglePoint.com or www.SingleSeed.com

Disclosures

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in the Company's filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM's actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.

Investor and Media Contacts:

AppSwarm, Inc.
888-886-8583
info@app-swarm.com

Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact:

SinglePoint, Inc.
Greg Lambrecht
602.481.1544

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as a creator of original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Companies Featured on the 420 Cannabis Investor Ideas have paid a one-time fee of Up to $1000 to be featured on the directory and is also a featured cannabis company for news and PR, social media .

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

#Patents in the #Cannabis Sector; A Growing Trend

#Patents in the #Cannabis Sector; A Growing Trend

#Stocks Mentioned: Veritas Pharma Inc. (CSE: $VRT.C; OTC: $VRTHF), ( $NEPT), ( $GWPH), ( $AXIM), (OTCQB: $LXRP; CSE: $LXX.C)

Point Roberts, WA, November 29, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and hemp stocks issues a sector news alert on patent news and developments and some of the key players.

Read this news in full at http://www.investorideas.com/news/2017/marijuana/11292CannabisPatents.asp

David Cohen, Ph.D., a patent consultant based in Oakland, California told Investor Ideas, “The US government’s “cannabis is illegal” stance has had little apparent dampening effect on patent activity per se, however it’s likely that the opening of markets by the progressive legalization of cannabis and entry into mainstream medicine will stimulate new levels of activity. The current approximately 1,500 cannabis-related US patent cases can be divided into groups: (1) compositions and preparation methods, (2) characterization of cannabinoids in terms of interaction with human cannabinoid receptors, and (3) treating diseases.”

He went on to say, “Small companies are focusing on novel formulations, disease treatment, and opening up new niches, such as production of cannabinoids by in fermentation vessels, methods used by the pharmaceutical industry for decades, for the production of complex drugs from genetically engineered cells.“

For investors following the sector that are taking note of Patents and IP as a key to success, recent news indicates the trend is definitely on the rise.

Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; Frankfurt: 2VP), an emerging pharmaceutical and IP development company, through its 80% owned research arm, Cannevert Therapeutics Ltd.  (“CTL”) filed a provisional patent application to US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a specific cannabis strain to enhance the actions of opioid analgesics.  An acknowledgement letter from the USPTO was received recently which provided a filing number of US 62/558,021 for this application.

Opioids are substances that are derived from the opium poppy plant.  They bind to the human body’s own opioid receptors to provide pain relief or ‘analgesia’ for patients with acute or chronic pain when prescribed legally; morphine is an example opioid analgesic.  Use of these drugs for a brief time is considered safe for pain management. However, when they are overprescribed and/or frequently misused, they produce a sense of euphoria along with relieving pain.  Hence, drug dependence can occur despite using them as prescribed over prolonged periods with the potential of fatal overdose.  Opioid overdose contributed to more than 33,000 deaths in 2015 according to US Centers for Disease Control and Prevention. Heroin and fentanyl are the most widely known opioids for their illegal, recreational use, abuse potential and fatal overdoses. Cannabis contains substances called cannabinoids that appear to bind to human body’s own cannabinoid receptors to also produce similar effects to those of the body’s opioids in mediating analgesia and behavioral effects.  However, they do not have the same drug dependence or overdose potential.  When cannabinoids and opioids are combined, they appear to augment each other’s effects synergistically.  Therefore, the combination may allow for opioids to be used at lower doses with fewer side effects for the treatment of pain and related addiction.  According Coherent Market Insights*, the global opioids market was approximately USD $17b in 2015 and is forecasted to moderately increase to near USD $26b in 2024.  It indicates that legal cannabis is expected to impact the opioids market growth as it gets adopted as a safe alternative pain relieving therapy to opioids and it is increasingly being used to address related addiction. According to the World Drug Report 2016, approximately 17 million people suffered from opioid drug abuse.

Veritas CEO, Dr. Lui Franciosi stated, “We are pleased with Cannevert’s latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for patients.”  Dr. Franciosi goes on to say, “This strain could be also potentially useful in addressing the current fentanyl crisis throughout North America.  If we’re targeting pain or opioid addiction, we want to deliver a scientifically tested, standardized product that clinicians can rely upon.”

*Global Opioids Agonist Drugs Market, By Product Type (Codeine, Fentanyl, Meperidine, Methadone, Morphine, Hydrocodone), Therapeutic Application (Pain Management, Cough Treatment, Diarrhea Treatment), and Geography - Trends, Analysis and Forecast till 2024 (Market Report – March 2017)

https://www.coherentmarketinsights.com/market-insight/opioids-market-135

Full news: http://www.investorideas.com/news/2017/marijuana/11281CannabisCSEVRT.asp

On Monday, Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT)(TSX:NEPT), announced an exclusive, worldwide and royalty bearing licensing agreement for the use of the MaxSimil® technology, a patented omega-3 fatty acid delivery technology and strong growth driver of Neptune's Solutions business, in combination with cannabis-derived products.

This new agreement allows Neptune to research, manufacture, formulate, distribute and sell monoglyceride omega-3-rich ingredients in combination with cannabis and/or cannabinoid-rich hemp-derived ingredients for medical and adult use applications.

As indicated in the past, the Company believes the MaxSimil® technology has the ability to enhance absorption of lipid-based and lipid soluble ingredients such as cannabinoids, essential fatty acids including EPA and DHA omega-3s, vitamins A, D, K and E, CoQ10 and others. This could be especially beneficial in increasing the absorption of ingredients which are not easily absorbed, such as cannabidiol (CBD).

"Neptune's strategy is to position itself in segments characterized by size and growth and the legal cannabis industry fits well with this and our wellness mission. Our core competencies in science, regulatory affairs, formulation, commercialization and oil extraction are tremendous foundations to position ourselves for success. Over the past year, MaxSimil® has been a proven winner in our Solutions Business and we are excited to apply this technology to cannabis-derived products. We will now begin investigating the impact of this innovative technology on the absorption and benefits of cannabis and cannabinoid ingredients," said Jim Hamilton, President & CEO of Neptune.

The Company submitted a written application to Health Canada to produce cannabis oil under the Access to Cannabis for Medical Purposes Regulations (ACMPR), which at this time has been confirmed by the agency as being at the Review and Security Clearance stage (stage 2 of 6). 

On October 31^st, 2017, Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX), a drug delivery platform innovator, announced “it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for the use of its technology as a delivery platform for all cannabinoids including THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications ("NSAIDs"); and nicotine.

This Notice of Allowance applies to the delivery of all active pharmacological ingredients ("APIs") Lexaria had been seeking.  While Lexaria has always had confidence in its patent applications, the rapid allowance for this broad API applicability is significantly ahead of Company expectations. As was true with the Company's existing non-psychoactive cannabinoid patent that was granted in 2016, Lexaria expects formal patent issuance within three to four months which is expected to provide protection until at least 2035.

Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,799, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof".

Earlier in October, AXIM® Biotechnologies, Inc. (OTC: AXIM), a company in cannabinoid research and development, announced that “the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/982,610, a patent that claims the use of an ophthalmic solution comprising cannabinoids for the treatment of glaucoma and symptomatic relief of conjunctival inflammation. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from AXIM’s patent application, 14/982,610, filed in December 2015.

AXIM® Biotech announced on March 21, 2017 that it retained the services of Ora®, Inc., a global Contract Research Organization (“CRO”), to perform the company’s product development (based on AXIM’s IP) in glaucoma and dry eye syndrome utilizing cannabinoid-based therapeutics through its AX-1603 and AX-1606 clinical programs.“

GW Pharmaceuticals plc (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on December 4^th, 2017 its fourth quarter and year-end financial results for the period ending 30 September, 2017.

Commenting on GW Pharmaceuticals, David Cohen, Ph.D said, “GW Pharmaceuticals (Salisbury, UK) is in a class by itself in terms of the size and scope of its patent portfolio. It now has a US portfolio of nearly 100 US references (applications and patents), which is nearly twice as large the portfolio of Abbvie (Redwood City, CA), the big pharma patent leader, and approximately four times the size of its nearest small company competitor. GW has focused its attention on medicinal cannabinoid formulations and on treatment of a wide range of clinical applications, including treatment of nausea, pain, inflammation, and epilepsy.

GW Pharmaceuticals has likely secured this patent position the old -fashioned way: by getting in early, understanding the science well, using foresight to identify open space in the market and in the patent landscape, developing a plan, sticking with it, and filing patents aggressively. Their effort, as reflected in patent filings, has been balanced between (1) a highly focused effort to develop medically appropriate formulations and methods of preparation, and (2) a broad view of medical conditions that may be responsive to cannabinoid treatment. As a model for smaller companies, a balance between a tight focus and a broader reach such as that may be instructive.”

http://files.shareholder.com/downloads/AMDA-1TW341/5636705522x0x923393/4961EF53-CD10-458C-9695-38D12E0507F1/GW_InvestorDeck.pdf

David Cohen, Ph.D., is a patent consultant based in Oakland, California. He has a background in biological sciences and experience in the pharmaceutical industry. At a career crossroads, he crossed over into patent law, and as a patent agent, now consults with biotechnology and medical device companies. He’s recently developed an interest in the cannabis patent landscape and has become affiliated with the Mazakali Capital Advisory Group of San Francisco.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

For a list of publicly traded marijuana and cannabis stocks visit:

http://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp

Investorideas.com cannabis/marijuana and hemp content now includes: http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the AI site Global Cannabis Investing at www.Globalcannabisinvesting.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as a creator of original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure this news is a paid for news release on the Investorideas.com newswire by Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF) Learn more about costs and our newswire service http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411 dvanzant@investorideas.com

Marijuana / Hemp Stocks

Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks